Review the offer
What makes an offer worth pausing?
You do not need to settle every medical question to pause a sale. Start with claims and details you can check.
A prescription medicine offered without a prescription
Federal law requires a prescription before a pharmacy supplies a prescription medicine. For the prescription rule, the check date was September 26, 2026.
Ask where the clinical assessment happens and who makes the prescribing decision. A payment step does not answer either question.
Approval language doing too much work
FDA (Food and Drug Administration) is the US body that reviews medicines.
Compounding means preparing the medicine to order; a drug company does not supply it as a ready-made product.
It is false to describe a medicine prepared by compounding as FDA-approved. This FDA position was checked on September 26, 2026.
Neither a business registration nor a drug listing with the FDA gives approval.
Ask for the product name tied to that approval claim. Geref was an older sermorelin medicine; its past approval does not approve a new pharmacy-made medicine.
A research label offered as a route to care
The FDA’s warning letters went to sellers whose websites promoted peptides for use by people despite labels limiting the products to research. The FDA said those offers broke the rules for selling drugs. These letters were checked through September 26, 2026.
A warning letter explains what the FDA says a seller did wrong. These letters are the agency’s allegations, not a court’s decision.
A research-only label is not a medical assessment. Keep it separate from a discussion of a prescribed, pharmacy-made medicine.
Names or answers that stay out of reach
Ask again for the health professional’s name and job title, the pharmacy’s name, the full charges, and a way to ask later questions.
Keep the offer on hold while a name or a claim cannot be checked. A reply that only repeats an advertising claim still leaves your question unanswered.